Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Post-Resection Benefit
This retrospective two-center comparison gives hepatology pharmacists real-world data on two distinct adjuvant strategies after curative hepatocellular carcinoma resection, informing regimen selection when guideline direction is limited.
Adjuvant therapies improve survival in high-risk liver cancer patients.
Hepatocellular carcinoma (HCC) patients at high risk of recurrence need effective adjuvant treatments after liver resection. Both postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) and lenvatinib plus tislelizumab (PA-LT) groups showed improved recurrence-free survival (RFS) and overall survival (OS) compared to liver resection (LR) alone, with no significant difference between PA-TACE and PA-LT. This study suggests both PA-TACE and PA-LT as effective adjuvant options for improving outcomes in high-risk HCC patients; however, head-to-head comparisons showed no superiority of one over the other. PA-TACE and PA-LT both enhance patient outcomes post-liver resection with no major safety concerns.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Feng X, Ao Y, Wang L, Chen K, Tang C, Huang C
Citation:Feng X, Ao Y, Wang L, et al. Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization versus lenvatinib plus tislelizumab in patients with BCLC stage 0 -B hepatocellular carcinoma after radical resection. Frontiers in immunology. 2026;17:1778330. doi:10.3389/fimmu.2026.1778330